High flow nasal cannula oxygen therapy in acute respiratory failure from acute exacerbation of fibrotic interstitial lung disease

Introduction. High flow nasal cannula oxygen therapy (HFNC) has become frequent in the treatment of patients with acute hypoxemic respiratory failure. Methods. Eleven patients with acute exacerbation of fibrotic interstitial lung disease (ILD) were treated with HFNC after failure of conventional the...

Full description

Bibliographic Details
Authors: Balzan, Fernanda Machado, Pacheco, Eder Chaves, Vieira, Fernando Nataniel, moretti Jr, Joares Luiz, Catarino, Bruna Maciel, Savi, Augusto
Format: article
Status:Published version
Publication Date:2020
Country:Brasil
Institution:Universidade Federal do Rio Grande do Sul (UFRGS)
Repository:Clinical and Biomedical Research
Language:English
OAI Identifier:oai:seer.ufrgs.br:article/98187
Online Access:https://seer.ufrgs.br/index.php/hcpa/article/view/98187
Access Level:Open access
Keyword:respiratory failure
interstitial lung disease
high flow nasal cannula
respiratory falilure
id BR_ddb02c8dc6841abc6b650fc7ac1bc8eb
oai_identifier_str oai:seer.ufrgs.br:article/98187
network_acronym_str BR
network_name_str Brasil
repository_id_str
spelling High flow nasal cannula oxygen therapy in acute respiratory failure from acute exacerbation of fibrotic interstitial lung diseaserespiratory failureinterstitial lung diseasehigh flow nasal cannularespiratory falilureIntroduction. High flow nasal cannula oxygen therapy (HFNC) has become frequent in the treatment of patients with acute hypoxemic respiratory failure. Methods. Eleven patients with acute exacerbation of fibrotic interstitial lung disease (ILD) were treated with HFNC after failure of conventional therapy (SatO2< 90% offering 100% FiO2 by non-rebreathing mask or noninvasive ventilation). Results. Ten patients had success with HFNC (not requiring orotracheal intubation) during emergency department admission. HFNC significantly improves clinical variables after 2h: respiratory rate decreased from 33 ± 6 breaths/min to 23 ± 3 breaths/min; PaO2 increased from 48.7 (38 - 59)mmHg to 81.1 (76 - 90) mmHg; PaO2/FiO2 ratio increased from 102.4 ± 32.2 to 136.6 ± 29.4; SatO2 increased from 85 (66 - 92)% to 96 ± (95 - 97)%. HFNC could be an effective alternative in the treatment of acute respiratory failure from acute exacerbations of fibrotic ILD.HCPA/FAMED/UFRGS2020-07-15info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionPeer-reviewed ArticleAvaliado por Paresapplication/pdfhttps://seer.ufrgs.br/index.php/hcpa/article/view/98187Clinical & Biomedical Research; Vol. 40 No. 1 (2020): Clinical and Biomedical ResearchClinical and Biomedical Research; v. 40 n. 1 (2020): Clinical and Biomedical Research2357-9730reponame:Clinical and Biomedical Researchinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSenghttps://seer.ufrgs.br/index.php/hcpa/article/view/98187/pdfCopyright (c) 2020 Clinical and Biomedical Researchinfo:eu-repo/semantics/openAccessBalzan, Fernanda MachadoPacheco, Eder ChavesVieira, Fernando Natanielmoretti Jr, Joares LuizCatarino, Bruna MacielSavi, Augusto2024-01-19T14:21:37Zoai:seer.ufrgs.br:article/98187Revistahttps://www.seer.ufrgs.br/index.php/hcpaPUBhttps://seer.ufrgs.br/index.php/hcpa/oai||cbr@hcpa.edu.br2357-97302357-9730opendoar:2024-01-19T14:21:37Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.none.fl_str_mv High flow nasal cannula oxygen therapy in acute respiratory failure from acute exacerbation of fibrotic interstitial lung disease
title High flow nasal cannula oxygen therapy in acute respiratory failure from acute exacerbation of fibrotic interstitial lung disease
spellingShingle High flow nasal cannula oxygen therapy in acute respiratory failure from acute exacerbation of fibrotic interstitial lung disease
Balzan, Fernanda Machado
respiratory failure
interstitial lung disease
high flow nasal cannula
respiratory falilure
title_short High flow nasal cannula oxygen therapy in acute respiratory failure from acute exacerbation of fibrotic interstitial lung disease
title_full High flow nasal cannula oxygen therapy in acute respiratory failure from acute exacerbation of fibrotic interstitial lung disease
title_fullStr High flow nasal cannula oxygen therapy in acute respiratory failure from acute exacerbation of fibrotic interstitial lung disease
title_full_unstemmed High flow nasal cannula oxygen therapy in acute respiratory failure from acute exacerbation of fibrotic interstitial lung disease
title_sort High flow nasal cannula oxygen therapy in acute respiratory failure from acute exacerbation of fibrotic interstitial lung disease
dc.creator.none.fl_str_mv Balzan, Fernanda Machado
Pacheco, Eder Chaves
Vieira, Fernando Nataniel
moretti Jr, Joares Luiz
Catarino, Bruna Maciel
Savi, Augusto
author Balzan, Fernanda Machado
author_facet Balzan, Fernanda Machado
Pacheco, Eder Chaves
Vieira, Fernando Nataniel
moretti Jr, Joares Luiz
Catarino, Bruna Maciel
Savi, Augusto
author_role author
author2 Pacheco, Eder Chaves
Vieira, Fernando Nataniel
moretti Jr, Joares Luiz
Catarino, Bruna Maciel
Savi, Augusto
author2_role author
author
author
author
author
dc.subject.por.fl_str_mv respiratory failure
interstitial lung disease
high flow nasal cannula
respiratory falilure
topic respiratory failure
interstitial lung disease
high flow nasal cannula
respiratory falilure
description Introduction. High flow nasal cannula oxygen therapy (HFNC) has become frequent in the treatment of patients with acute hypoxemic respiratory failure. Methods. Eleven patients with acute exacerbation of fibrotic interstitial lung disease (ILD) were treated with HFNC after failure of conventional therapy (SatO2< 90% offering 100% FiO2 by non-rebreathing mask or noninvasive ventilation). Results. Ten patients had success with HFNC (not requiring orotracheal intubation) during emergency department admission. HFNC significantly improves clinical variables after 2h: respiratory rate decreased from 33 ± 6 breaths/min to 23 ± 3 breaths/min; PaO2 increased from 48.7 (38 - 59)mmHg to 81.1 (76 - 90) mmHg; PaO2/FiO2 ratio increased from 102.4 ± 32.2 to 136.6 ± 29.4; SatO2 increased from 85 (66 - 92)% to 96 ± (95 - 97)%. HFNC could be an effective alternative in the treatment of acute respiratory failure from acute exacerbations of fibrotic ILD.
publishDate 2020
dc.date.none.fl_str_mv 2020-07-15
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Peer-reviewed Article
Avaliado por Pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://seer.ufrgs.br/index.php/hcpa/article/view/98187
url https://seer.ufrgs.br/index.php/hcpa/article/view/98187
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://seer.ufrgs.br/index.php/hcpa/article/view/98187/pdf
dc.rights.driver.fl_str_mv Copyright (c) 2020 Clinical and Biomedical Research
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2020 Clinical and Biomedical Research
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv HCPA/FAMED/UFRGS
publisher.none.fl_str_mv HCPA/FAMED/UFRGS
dc.source.none.fl_str_mv Clinical & Biomedical Research; Vol. 40 No. 1 (2020): Clinical and Biomedical Research
Clinical and Biomedical Research; v. 40 n. 1 (2020): Clinical and Biomedical Research
2357-9730
reponame:Clinical and Biomedical Research
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Clinical and Biomedical Research
collection Clinical and Biomedical Research
repository.name.fl_str_mv Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv ||cbr@hcpa.edu.br
_version_ 1853660295484932096
score 15.301603

Similar Items